




The relative strengths and weaknesses of Rigel Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rigel Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Rigel Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 108% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	115,903
Cost of Goods Sold	1,749
Intangible Assets	0
Liabilities, Current	65,211
Liabilities, Non-Current	43,236
Other Assets	17,519
Other Compr. Net Income	-51
Other Expenses	5,027
Other Liabilities	39,448
Other Net Income	684
Other Revenues	120,242
Property and Equipment	857
Research and Development	60,272
Selling, General and Administrative Expense	112,451

Output Variable	Value in 1000 USD
Assets	134,279
Liabilities	147,895
Expenses	179,499
Revenues	120,242
Stockholders Equity	-13,616
Net Income	-58,573
Comprehensive Net Income	-58,598
BaseVar	291,325
ECR before Limited Liability	-63%
Economic Capital Ratio	137%